Seltorexant - Janssen Pharmaceuticals/Minerva Neurosciences

Drug Profile

Seltorexant - Janssen Pharmaceuticals/Minerva Neurosciences

Alternative Names: JNJ-42847922; JNJ-7922; MIN-202

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Minerva Neurosciences
  • Class Antidepressants; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia; Major depressive disorder

Most Recent Events

  • 11 Apr 2018 Janssen Research & Development plans a phase I trial for Healthy volunteers in Belgium , (NCT03494907)
  • 09 Feb 2018 Janssen Research & Development initiates enrolment in a phase I trial in USA (PO) (NCT03438461)
  • 02 Feb 2018 Janssen Research & Development terminates a phase II trial in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in USA (PO), due to investigational product packaging issue (NCT03321526)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top